Veracyte Statistics
Total Valuation
Veracyte has a market cap or net worth of $2.19 billion. The enterprise value is $1.95 billion.
| Market Cap | 2.19B |
| Enterprise Value | 1.95B |
Important Dates
The next estimated earnings date is Tuesday, August 5, 2025, after market close.
| Earnings Date | Aug 5, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Veracyte has 78.31 million shares outstanding. The number of shares has increased by 8.46% in one year.
| Current Share Class | 78.31M |
| Shares Outstanding | 78.31M |
| Shares Change (YoY) | +8.46% |
| Shares Change (QoQ) | +0.19% |
| Owned by Insiders (%) | 0.49% |
| Owned by Institutions (%) | 106.59% |
| Float | 77.93M |
Valuation Ratios
The trailing PE ratio is 67.42 and the forward PE ratio is 21.85. Veracyte's PEG ratio is 0.91.
| PE Ratio | 67.42 |
| Forward PE | 21.85 |
| PS Ratio | 4.66 |
| Forward PS | 4.29 |
| PB Ratio | 1.83 |
| P/TBV Ratio | 6.40 |
| P/FCF Ratio | 27.88 |
| P/OCF Ratio | 24.46 |
| PEG Ratio | 0.91 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 31.32, with an EV/FCF ratio of 24.86.
| EV / Earnings | 59.02 |
| EV / Sales | 4.21 |
| EV / EBITDA | 31.32 |
| EV / EBIT | 49.95 |
| EV / FCF | 24.86 |
Financial Position
The company has a current ratio of 5.10, with a Debt / Equity ratio of 0.04.
| Current Ratio | 5.10 |
| Quick Ratio | 4.54 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | 0.69 |
| Debt / FCF | 0.64 |
| Interest Coverage | 19,524.50 |
Financial Efficiency
Return on equity (ROE) is 2.86% and return on invested capital (ROIC) is 2.05%.
| Return on Equity (ROE) | 2.86% |
| Return on Assets (ROA) | 1.94% |
| Return on Invested Capital (ROIC) | 2.05% |
| Return on Capital Employed (ROCE) | 3.15% |
| Revenue Per Employee | $562,370 |
| Profits Per Employee | $40,108 |
| Employee Count | 824 |
| Asset Turnover | 0.37 |
| Inventory Turnover | 6.43 |
Taxes
In the past 12 months, Veracyte has paid $2.03 million in taxes.
| Income Tax | 2.03M |
| Effective Tax Rate | 5.79% |
Stock Price Statistics
The stock price has increased by +33.76% in the last 52 weeks. The beta is 2.09, so Veracyte's price volatility has been higher than the market average.
| Beta (5Y) | 2.09 |
| 52-Week Price Change | +33.76% |
| 50-Day Moving Average | 29.49 |
| 200-Day Moving Average | 35.11 |
| Relative Strength Index (RSI) | 46.99 |
| Average Volume (20 Days) | 965,441 |
Short Selling Information
The latest short interest is 5.47 million, so 6.98% of the outstanding shares have been sold short.
| Short Interest | 5.47M |
| Short Previous Month | 5.21M |
| Short % of Shares Out | 6.98% |
| Short % of Float | 7.02% |
| Short Ratio (days to cover) | 4.77 |
Income Statement
In the last 12 months, Veracyte had revenue of $463.39 million and earned $33.05 million in profits. Earnings per share was $0.41.
| Revenue | 463.39M |
| Gross Profit | 326.41M |
| Operating Income | 39.05M |
| Pretax Income | -54.79M |
| Net Income | 33.05M |
| EBITDA | 62.28M |
| EBIT | 39.05M |
| Earnings Per Share (EPS) | $0.41 |
Balance Sheet
The company has $287.36 million in cash and $50.50 million in debt, giving a net cash position of $236.85 million or $3.02 per share.
| Cash & Cash Equivalents | 287.36M |
| Total Debt | 50.50M |
| Net Cash | 236.85M |
| Net Cash Per Share | $3.02 |
| Equity (Book Value) | 1.19B |
| Book Value Per Share | 15.26 |
| Working Capital | 308.03M |
Cash Flow
In the last 12 months, operating cash flow was $89.42 million and capital expenditures -$10.97 million, giving a free cash flow of $78.45 million.
| Operating Cash Flow | 89.42M |
| Capital Expenditures | -10.97M |
| Free Cash Flow | 78.45M |
| FCF Per Share | $1.00 |
Margins
Gross margin is 70.44%, with operating and profit margins of 8.43% and 7.13%.
| Gross Margin | 70.44% |
| Operating Margin | 8.43% |
| Pretax Margin | 7.57% |
| Profit Margin | 7.13% |
| EBITDA Margin | 13.44% |
| EBIT Margin | 8.43% |
| FCF Margin | 16.93% |
Dividends & Yields
Veracyte does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -8.46% |
| Shareholder Yield | -8.46% |
| Earnings Yield | 1.51% |
| FCF Yield | 3.59% |
Analyst Forecast
The average price target for Veracyte is $39.89, which is 42.82% higher than the current price. The consensus rating is "Buy".
| Price Target | $39.89 |
| Price Target Difference | 42.82% |
| Analyst Consensus | Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (5Y) | 6.58% |
| EPS Growth Forecast (5Y) | 46.49% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Veracyte has an Altman Z-Score of 12.24 and a Piotroski F-Score of 6.
| Altman Z-Score | 12.24 |
| Piotroski F-Score | 6 |